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Mark Oyama, DVM, with Stanley, a Doberman. Dr. Oyama, a professor of cardiology at Penn Vet, is 
working to ensure a heart disease, commonly found in Dobermans, is controlled as effectively as possible.
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D
oberman pinschers are stately, strong and 
intelligent, seemingly unflappable. Yet members 
of this breed are more likely than any other to 
succumb to an insidious, inherited condition 
that can silently kill.
Dilated cardiomyopathy (DCM) is the 
second most common acquired heart disease seen in dogs, 
behind mitral valve disease. It’s particularly prevalent in 
Dobermans. 
“As many as 40 percent of Doberman pinschers are going 
to get dilated cardiomyopathy at some point in their life,” said 
Mark Oyama, DVM, a professor of cardiology at Penn Vet. “So 
clearly it’s a big problem for the breed.”
DCM, which is typically an inherited condition in 
canines, also commonly strikes other large breeds such as Irish 
Wolfhounds and Great Danes. Fortunately for these dogs 
and their owners, Dr. Oyama is one of a growing number of 
researchers with a goal of finding better ways to screen and treat 
pets that have or are likely to develop DCM.
Among the challenges of this pursuit is the disease’s hidden 
nature. 
“Oftentimes a dog will be developing or have dilated 
cardiomyopathy and yet show no outward signs of it,” said 
Dr. Oyama. “So you have owners who think their dog is 
completely normal and yet they’re walking around with heart 
disease.”
Sometimes, the first overt sign that a dog has DCM is 
it suddenly collapses and dies. But many dogs do display 
symptoms, which may include labored breathing, coughing, 
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fainting, exercise intolerance, restlessness and lethargy. All of 
these result from the central feature of DCM, which is the 
weakening of the heart muscle. 
While researchers don’t fully understand the mechanism of 
disease, they do know it has to do with a malfunction in the 
way that heart muscle cells operate at their fundamental or 
cellular level. As a result of these disruptions on the molecular 
and cellular levels, the chambers of the heart dilate and their 
walls thin. The heart’s pumping action weakens and fails to 
adequately circulate blood through the body. This, in turn, leads 
to congestive heart failure. 
Sudden cardiac death can occur without any previous 
symptoms because a heart damaged by DCM may beat in an 
abnormal rhythm and arrest. The disease can be devastating for 
dog owners who would have otherwise expected to have several 
more years with their pet; DCM can strike Dobermans as young 
as two years old and most dogs die within a year of diagnosis.
towarD earLy DiagnoSiS 
Currently, the gold standard for DCM diagnosis is to perform 
a cardiac ultrasound (echocardiogram) and to monitor the heart 
rhythm for 24 hours with an ambulatory electrocardiogram, 
known as a Holter monitor. These screenings are not 
inexpensive and while the expense may be justifiable for 
the owner of a single Doberman, it could be prohibitive for 
breeders who may wish to screen many dogs at once.
The stakes are high for early diagnosis, because veterinarians 
can intervene with drugs such as pimobendan, beta-blockers, 
diuretics and ACE inhibitors that can slow the disease’s 
progression. Thus, much of Dr. Oyama’s research on DCM has 
focused on developing more accurate and less expensive ways 
to diagnose the disease. 
“One of the things that we looked at most recently is trying 
to find out if you could do a blood test that would help you 
decide if your dog has a high likelihood or a low likelihood 
of having cardiomyopathy,” said Dr. Oyama. “That would 
provide a kind of middle ground between doing nothing and 
doing a full-blown diagnostic workup.”
In a publication just out in the Journal of Veterinary Internal 
Medicine, Dr. Oyama and former Penn Vet resident Gretchen 
Singletary, now a veterinary specialist at Cornell University 
Veterinary Specialists, along with colleagues, describe a blood 
test that can help discern whether a dog is in the early stages 
of DCM. Examining 155 asymptomatic dogs, the researchers 
measured blood concentrations of N-terminal pro-brain 
natriuretic peptide, or NT-proBNP. The heart releases this 
peptide when it is under stress, and other researchers have used 
it as a marker of cardiac dysfunction in humans.
In the study, the researchers found that dogs with high 
levels of NT-proBNP were more likely to have DCM and had 
much shorter survival times than those with lower levels. This 
assay alone, however, did not always reliably predict a dog’s 
likelihood of being diagnosed with DCM without an ECG. A 
solution to the lack of sensitivity was to pair the blood test with 
An X-ray of a dog’s heart with DCM.
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while Dr. Mark Oyama seeks better ways to determine whether or not a dog has dilated cardiomyopathy (DCM), Meg Sleeper, VMD is refining approaches to treating DCM and other 
heart conditions that may restore near-normal function to the 
heart muscle. What she finds may reach beyond the veterinary 
profession to improve human lives as well.
For nearly a decade, Dr. Sleeper, associate professor of 
cardiology, has worked with colleagues at Penn and elsewhere to 
develop gene therapy techniques to treat cardiac disease in dogs 
and cats. Gene therapy aims to correct disease-causing genetic 
abnormalities by using a non-pathogenic virus to “infect” 
specific cells in a patient with a healthy version of a gene. 
One beauty of the approach is that researchers needn’t 
understand the exact molecular pathway that goes awry — and 
for DCM, scientists don’t yet have this detailed knowledge. 
Instead, they can zoom to the end of the pathway, correcting 
the ultimate problem. For DCM, that means targeting the 
protein pump that shuttles calcium in and out of cells. Using 
gene therapy that helps boost levels of calcium inside the 
cell, researchers can ensure the heart muscle maintains strong 
contractions, staving off congestive heart failure.
“With gene therapy what we’re doing is trying to get the 
heart muscle to produce a protein of interest,” said Dr. Sleeper. 
“So instead of having to give a drug every day, the muscle 
cells just produce the molecule, in essence becoming the drug 
manufacturer for us.”
Two different genes have functioned as these genetic “drugs” 
in Dr. Sleeper’s early trials. One, called S100A1, enhances 
calcium movement into heart muscle cells. The other blocks the 
activity of the gene phospholamban, which normally reduces 
movement of calcium into cells. The initial tests, conducted in 
about 60 dogs, look promising. 
“With the studies we’ve done so far we can get about 60 to 70 
percent of the heart cells to express the genes we’re introducing,” 
she said. “I’m hopeful that that is enough for a dog with DCM 
to experience a big difference in their heart function.”
This initial phase of testing has also shown that the treatment 
is safe in a variety of canine breeds, most of which did not have 
DCM. Dr. Sleeper now has grant applications submitted with the 
hope of experimentally treating Dobermans that do have DCM. 
Not only might success in these trials bode well for dogs with 
DCM, but also in humans with DCM and other heart conditions.
“If it turns out that we get really great results with either 
phospholamban or S100A1 or both, then I think that gives 
researchers really useful information for treating humans,” Dr. 
Sleeper notes.  
In people, DCM can be inherited but can also develop after a 
heart attack or coronary disease. DCM can also be one symptom 
of Duchenne muscular dystrophy, which affects one out of every 
3,500 boys and is caused by a mutation in the dystrophin gene. 
Together with Lee Sweeney, PhD, the William Maul Measey 
Professor and chairman of physiology at Penn Medicine, and 
others, Dr. Sleeper has used gene therapy to correct the problem 
in the muscle tissue of dogs with the disease — an important 
animal model for humans with muscular dystrophy.
Breakthroughs that rely on gene therapy are steadily increasing 
in number. Another one of Dr. Sleeper’s collaborators, Penn 
Vet’s Mark Haskins, VMD, PhD, has had excellent results 
replacing a malfunctioning enzyme in dogs with a devastating 
lysosomal storage disease. That treatment may soon enter clinical 
trials in children with the fatal condition. 
Such promising results with gene therapy put Dr. Sleeper and 
other Penn Vet faculty at the cutting edge of medicine. “These 
kinds of approaches,” she said, “give us a whole different way of 
looking at disease.”
—BY KATHERINE UNGER BAILLIE 
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Cardiac ultrasound of 
a dog with DCM.
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the Holter monitor — a combination that resulted in a very 
specific and sensitive way to pre-screen dogs for disease. This 
two-faceted approach may offer owners a less pricey alternative 
to having vets perform an echocardiogram in addition to the 
Holter monitor to see if their dog requires further examination.
geneS for riSk
Another strategy for early diagnosis of DCM is to screen dogs 
for genes that predispose them to the condition. 
“It seems realistic to think that there are breed-specific genetic 
abnormalities that predispose Doberman pinschers to get dilated 
cardiomyopathy,” said Dr. Oyama, “because the condition is so 
prevalent within the breed.”  
But even though there are hundreds of genes that have been 
linked in humans with DCM, veterinary researchers have just 
begun to discover parallel genes in dogs. 
The search for these mutations is made difficult because large 
populations are generally required to do genome-wide searches 
for abnormal genes. A breakthrough on the genetic front came 
earlier this year. Dr. Oyama was part of a team that reported on 
their discovery in a study led by Dr. Kathryn Meurs of North 
Carolina State University’s College of Veterinary Medicine.  
Writing in the journal Human Genetics, Dr. Meurs’ team 
screened 48 healthy Dobermans and 48 Dobermans with 
diagnosed DCM for gene mutations that appeared prevalent in 
the sick dogs. In their analysis, they found one mutation that 
stood out in the DCM dogs. This abnormality, affecting the 
gene PDK4, appears to alter the metabolism of the heart, shifting 
it from burning fat — the heart’s preferred fuel — to sugar. 
“Ultimately, this change could result in an energy-starved 
state,” the authors write, leading to a weakening of the heart’s 
contraction. 
It’s clear that this one mutation is not responsible for all cases 
of inherited DCM in Dobermans — 18 percent of the animals 
with the disease in the study did not have the mutation. This 
fact complicates the hope for a quick genetic screening test 
for mutations that predisposes a dog to the disease. Such a test 
would be especially valuable for breeders, who would be able to 
use the procedure to identify individual animals to keep out of 
their breeding pool. 
a Brighter future
Despite the cruel rapidity of DCM, a dog diagnosed with the 
disease today is better off than it would have been 10 years ago. 
Researchers including Dr. Oyama continue to seek therapies that 
will dramatically decelerate the disease’s progression. Meanwhile, 
other scientists, including Margaret M. Sleeper, VMD, associate 
professor at Penn Vet, are aiming for treatments using gene 
therapy (see sidebar). 
“A long time ago there simply weren’t enough people who 
were interested in studying cardiac diseases in dogs,” said Dr. 
Oyama. “Now you have a critical mass of investigators, many 
of whom collaborate and can look at multiple aspects of the 
disease.” 
Together, these veterinarian-scientists may soon render DCM 
an eminently treatable — and one day, curable — condition. 
continued from page 5
